Skip to main content

New Drug Approvals 2013 - Pt. VI - Gadoterate Meglumine (DotaremTM)






ATC Code: V08CA02
Wikipedia: Gadoteric Acid

On March 20th 2013, FDA approved Gadoteric Acid (as the meglumine salt; tradename: Dotarem; research code: P 449; CHEMBL: CHEMBL2219415), a gadolinium-based contrast agent (GBCA) indicated for intravenous use with magnetic resonance imaging (MRI) in brain (intracranial), spine and associated tissues of patients ages 2 years and older, to detect and visualize areas with disruption of the blood brain barrier (BBB) and/or abnormal vascularity of the central nervous system (CNS).

When placed in a magnetic field, Gadoteric Acid develops a magnetic moment. This magnetic moment enhances the relaxation rates of water protons in its vicinity, leading to an increase in signal intensity (brightness) of tissues. Gadoteric Acid enhances the contrast in MRI images, by shortening the spin-lattice (T1) and the spin-spin (T2) relaxation times.

Other GBCAs have already been approved by FDA for use in patients undergoing CNS MRI and these include Gadopentetate Dimeglumine (approved in 1988 under the tradename Magnevist; ChEMBL: CHEMBL1200431; PubChem: CID55466; ChemSpider: 396793), Gadoteridol (approved in 1992 under the tradename Prohance; ChEMBL: CHEMBL1200593; PubChem: CID60714; ChemSpider: 54719), Gadodiamide (approved in 1993 under the tradename Omniscan; ChEMBL: CHEMBL1200346; PubChem: CID153921; ChemSpider: 135661), Gadoversetamide (approved in 1999 under the tradename Optimark; ChEMBL: CHEMBL1200457; PubChem: CID444013; ChemSpider: 392041), Gadobenate Dimeglumine (approved in 2004 under the tradename Multihance; ChEMBL: CHEMBL1200571; PubChem: CID49799998; ChemSpider: 25046318) and Gadobutrol (approved in 2011 under the tradename Gadavist; ChEMBL: CHEMBL2218860; PubChem: CID15814656; ChemSpider: 26330337).



Gadoteric Acid is a macrocyclic ionic contrast agent, consisting of the chelating agent DOTA and gadolinium (Gd3+).
IUPAC: gadolinium(3+);2-[4,7,10-tris(carboxymethyl)-1,4,7,10-tetrazacyclododec-1-yl]acetic acid
Canonical Smiles: [Gd+3].OC(=O)CN1CCN(CC(=O)[O-])CCN(CC(=O)[O-])CCN(CC(=O)[O-])CC1
InChI: InChI=1S/C16H28N4O8.Gd/c21-13(22)9-17-1-2-18(10-14(23)24)5-6-20(12-16(27)28)8-7-19(4-3-17)11-15(25)26;/h1-12H2,(H,21,22)(H,23,24)(H,25,26)(H,27,28);/q;+3/p-3

The recommended dose of Gadoteric Acid is 0.2 mL/kg (0.1 mmol/kg) body weight administrated as an intravenous bolus injection at a flow rate of approximately 2 mL/second for adults and 1-2 mL/second for pediatric patients. Gadoteric Acid has a volume of distribution of 179 mL/kg and 211 mL/kg in female and male subjetcs, respectively, roughly equivalent to that of extracellular water, and an elimination half-life of about 1.4 hr and 2.0 hr in female and male subjects, respectively. Gadoteric Acid does not undergo plasma protein binding and it is not known to be metabolized. It is excreted primarily in the urine with 72.9% and 85.4% eliminated within 48 hours in female and male subjects, respectively. In healthy subjects, the renal and total clearance rates are comparable, with a renal clearance of 1.27 mL/min/kg and 1.40 mL/min/kg in female and male subjects, respectively, and a total clearance of 1.74 mL/min/kg and 1.64 mL/min/kg in female and male subjects, respectively.

All GBCAs, including Gadoterate Meglumine, carry a boxed warning about the risk of nephrogenic systemic fibrosis (NSF), a condition associated with the use of GBCAs in certain patients with kidney disease.

The license holder for Gadoterate Meglumine is Guerbet LLC and the prescribing information can be found here (Gadoteric Acid is also approved in Europe and the SPC can be found here).

Comments

Popular posts from this blog

ChEMBL 34 is out!

We are delighted to announce the release of ChEMBL 34, which includes a full update to drug and clinical candidate drug data. This version of the database, prepared on 28/03/2024 contains:         2,431,025 compounds (of which 2,409,270 have mol files)         3,106,257 compound records (non-unique compounds)         20,772,701 activities         1,644,390 assays         15,598 targets         89,892 documents Data can be downloaded from the ChEMBL FTP site:  https://ftp.ebi.ac.uk/pub/databases/chembl/ChEMBLdb/releases/chembl_34/ Please see ChEMBL_34 release notes for full details of all changes in this release:  https://ftp.ebi.ac.uk/pub/databases/chembl/ChEMBLdb/releases/chembl_34/chembl_34_release_notes.txt New Data Sources European Medicines Agency (src_id = 66): European Medicines Agency's data correspond to EMA drugs prior to 20 January 2023 (excluding vaccines). 71 out of the 882 newly added EMA drugs are only authorised by EMA, rather than from other regulatory bodies e.g.

New SureChEMBL announcement

(Generated with DALL-E 3 ∙ 30 October 2023 at 1:48 pm) We have some very exciting news to report: the new SureChEMBL is now available! Hooray! What is SureChEMBL, you may ask. Good question! In our portfolio of chemical biology services, alongside our established database of bioactivity data for drug-like molecules ChEMBL , our dictionary of annotated small molecule entities ChEBI , and our compound cross-referencing system UniChem , we also deliver a database of annotated patents! Almost 10 years ago , EMBL-EBI acquired the SureChem system of chemically annotated patents and made this freely accessible in the public domain as SureChEMBL. Since then, our team has continued to maintain and deliver SureChEMBL. However, this has become increasingly challenging due to the complexities of the underlying codebase. We were awarded a Wellcome Trust grant in 2021 to completely overhaul SureChEMBL, with a new UI, backend infrastructure, and new f

Accessing SureChEMBL data in bulk

It is the peak of the summer (at least in this hemisphere) and many of our readers/users will be on holiday, perhaps on an island enjoying the sea. Luckily, for the rest of us there is still the 'sea' of SureChEMBL data that awaits to be enjoyed and explored for hidden 'treasures' (let me know if I pushed this analogy too far). See here and  here for a reminder of SureChEMBL is and what it does.  This wealth of (big) data can be accessed via the SureChEMBL interface , where users can submit quite sophisticated and granular queries by combining: i) Lucene fields against full-text and bibliographic metadata and ii) advanced structure query features against the annotated compound corpus. Examples of such queries will be the topic of a future post. Once the search results are back, users can browse through and export the chemistry from the patent(s) of interest. In addition to this functionality, we've been receiving user requests for  local (behind the